Bristol-Myers Squibb Company announced topline results from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus...
Read moreChengdu Pioneer Drug Development Co., Ltd. announced a multi-year, long-term, new drug research and development collaboration with Aduro Biotech to...
Read moreCARsgen Therapeutics (CARsgen), a global leader in developing chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors announced its...
Read moreMotif Bio plc ,the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced that the last patient has completed...
Read moreMitsubishi Tanabe Pharma America, Inc. announced RADICAVA ™ (edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis...
Read moreCMP Pharma announced that the US FDA has granted final approval of the company’s NDA for CaroSpir® (Spironolactone Oral Suspension,...
Read moreTakeda Pharma and Molecular Templates, Inc. announced a collaboration agreement for oncology drug discovery programs. The collaboration will apply Molecular...
Read moreIntercept Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral...
Read moreX4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat...
Read moreTeva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announce top-line results in a Phase II study of topical TV-45070 in...
Read morePharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
© 2017 Copyright © Valuemediaservices 2017 All rights reserved.